Online inquiry

IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3036MR)

This product GTTS-WQ3036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3036MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ706MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ6113MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ11176MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ11462MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12045MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ7471MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ9728MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ4236MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW